Session 1.4

Medicines Regulation and Medical Education

Hildrun Sundseth
President
European Institute of Women’s Health
Objectives of Session 1.4

• This session will concentrate on current medicines regulations, clinical trials, legislation, good clinical practice guidelines and research policies and how these support implementation of sex and gender aspects.

• It will also discuss the integration of sex and gender in medical training
1. Medical Regulation

Defining the context

Dr. Thorsten Vetter
Scientific Administrator
European Medicines Agency
2. How are Sex & Gender issues included in the regulatory assessment?

- Do we currently have data from clinical trials for a robust analysis of S&G?
- How will inclusion of women in Clinical Trials allow for a more robust analysis?
- Present situation, new Clinical Trials Regulation?
- How do Ethics Committees consider the S&G perspective?
- Are women included as members of Ethics Committees?
- Do we need Guidelines for Ethics Committees to address these aspects?
- How do GCP Guidelines include S&G considerations?
3. How can we fulfill unmet medical needs?

- What can we do about the unmet medical need of pregnant women who have to take medicines for their chronic condition?
- Include them in Clinical Trials under strict conditions?
- Pregnancy registers, post-marketing surveillance?
- How can IMI 2 include S&G in their research projects?
4. Medical Education

- What is the current CPME position regarding S&G in medical training?
- How can medical associations promote the integration of S&G in general practice and specialty training?
- How to integrate S&G in continuous medical education (CME) across Europe?
- What tools are available to help integrate S&G into medical education?
4. Medical Education

• How do we campaign for S&G guidelines for medical education at EU and national level? At bachelor/master level?

• What are the education/training requirements of clinical trial experts and regulators to include S&G considerations?

• How can we involve medical students in the process?
This project, the European Gender Medicine Network (EUGenMed), has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No 602050.